Bayer’s 70% Manager Cut: Bill Anderson’s $2.2B Test of Flat Leadership
Most big companies don’t have a talent problem. They have 11,500 managers standing between capable people and a decision — and Bayer just proved how far a CEO can go to fix it.
Most big companies don’t have a talent problem. They have 11,500 managers standing between capable people and a decision.
Bayer CEO Bill Anderson has taken the axe to that problem, cutting the company’s manager ranks from roughly 16,000 to 4,500. That is a 70% reduction inside an 88,000-person business. Plenty of CEOs talk about empowerment. Anderson has made thousands of management jobs disappear and told the people left behind to stop behaving like human approval buttons.
That takes nerve. It also creates a very obvious question: once you have flattened the place, can you actually grow it?
Bayer has removed the furniture. Now it has to build a business.
Bayer is not a scrappy startup with a few dozen staff and a ping-pong table. It is a 163-year-old health-science giant with pharmaceuticals, consumer health and crop science businesses, a complicated legacy, and the sort of institutional gravity that normally makes change happen at the speed of a committee meeting.
Anderson became Bayer CEO in June 2023, inheriting a company carrying heavy litigation uncertainty, debt pressure and businesses that needed sharper execution. His answer was not another glossy transformation deck. It was an operating-model rebuild Bayer calls Dynamic Shared Ownership.
The core changes are straightforward, even if they are bloody difficult to execute:
- Manager numbers were cut from about 16,000 to 4,500. - Hierarchy and annual budgeting were replaced in many areas by roughly 5,000 smaller teams working in 90-day cycles. - Bayer says it has reduced management by about two-thirds and materially cut its organisational layers. - Decision-making is being pushed closer to the work, with Anderson saying the aim is for 95% of decisions to sit at the bottom of the organisation rather than be “delegated” down through a hierarchy.
That last distinction matters. Delegation is often a manager handing down a task while retaining the right to overrule it. Real authority means the team owns the outcome, the trade-offs and the consequences.
Bayer’s old model will sound painfully familiar to anyone who has worked in a large business: layers of bosses, fixed annual budgets, tiny teams reporting to people whose own job is mainly reporting upwards, and a lot of activity dressed up as control.
It is expensive. More importantly, it is slow.
Anderson’s approach is built on a blunt belief: leaders should set direction, not attempt to pre-decide every move made by people closer to customers, products, laboratories or farms. That is not revolutionary in a management textbook. It is revolutionary when a chief executive actually reorganises a global company around it.
The numbers say Bayer has bought itself a chance — not a victory lap
Cutting management is easy to applaud from a distance because everyone has a story about a useless boss. But a flatter organisation is only a better organisation if it becomes faster, more accountable and more commercially effective.
Bayer’s scoreboard is mixed, which is precisely why this is worth watching.
The company reported 2025 sales of €45.5 billion and free cash flow of €2.1 billion. For 2026, it guided to sales of €45 billion to €47 billion at constant currencies, or currency- and portfolio-adjusted growth of 0% to 3%.
That is not a business firing on every cylinder. It is a turnaround still doing the hard yards.
Fortune reported that Bayer shares had risen 57% over the preceding year, although the stock was still flat over the prior three years. Investors have clearly rewarded the improvement story. But shareholders are not buying a flatter org chart. They are buying the possibility that Bayer can convert operational simplification into sustainable growth, stronger profitability and more strategic freedom.
That is where the latest move matters: Bayer announced a $2.2 billion investment in a new Ohio manufacturing site. A company does not make that sort of commitment because it has become better at internal workshops. It does it because management believes the enterprise can execute, sell and earn a return on substantial capital.
The leadership test is now unforgiving. Bayer has done the demolition. It has to prove the building is structurally sound.
Flattening a company is not the same as making it leaderless
Here is where a lot of executives stuff it up.
They hear “fewer managers” and conclude that everybody should be autonomous, free and vaguely empowered. Then six months later, nobody knows who can make a call, priorities multiply, strong personalities take over, and the business discovers it has replaced bureaucracy with chaos.
Anderson’s model is more demanding than that.
A flatter company needs clearer strategy, not less of it. It needs fewer goals, not a thousand goals distributed across 5,000 teams. It needs decision rights written down in plain English. It needs visible commercial data. And it needs leaders who coach hard, remove obstacles and make trade-offs — rather than quietly recreating the hierarchy through meetings, Slack messages and “alignment” calls.
Bayer has already acknowledged a difficult truth: more authority does not automatically make people willing to make hard decisions. Anderson told Fortune that the company’s culture had been somewhat soft on decisiveness and what he called courageous authenticity.
Good. That is an honest diagnosis.
Most businesses do not fail because people cannot see the problem. They fail because too many people can see it and nobody feels authorised to own the unpleasant answer.
You can remove three layers of approval, but if staff still believe a mistake will end their career while indecision carries no cost, they will keep sending decisions upstairs. The org chart changes; the behaviour does not.
That is why leadership in a flatter company becomes more, not less, important. You need managers who can handle ambiguity, give candid feedback, protect the team from political noise and be ruthless about priorities. The title might disappear. The work absolutely does not.
The overlooked angle: Bayer is attacking management’s status problem
There is a dirty little secret in corporate life: many companies treat becoming a manager as the only respectable promotion.
You are brilliant at sales? Become a manager. Great engineer? Manage people. Strong scientist? Start approving leave requests and sitting in forecasting meetings. The reward for being good at your job becomes being removed from the job you are good at.
That creates two predictable problems. First, companies manufacture managers who never wanted to manage. Second, people protect managerial turf because title, pay and status are tied to the size of their team.
Bayer’s reduction forces a different question: what is the value of this leadership role?
If a manager’s main contribution is collecting updates, chasing templates and forwarding decisions, the role should go. Full stop. Software, shared data and competent team members can do that better.
But if the manager makes people better, resolves conflict early, allocates resources intelligently, builds future leaders and brings clarity under pressure, that person is worth a fortune.
The best management model is not one with the fewest managers. It is one where every manager has a job that justifies their cost and authority.
Anderson is also making a useful statement by ranking Bayer’s priorities as mission first, employees second, shareholders third and senior management last. Some people will find that order provocative. I do not.
Senior management should be last because it exists to serve the mission and make employees more effective — not to preserve its own prestige, parking spaces or headcount.
The contrarian view: 90-day cycles can become corporate ADHD
I like the direction of Bayer’s model. But I would not blindly copy every bit of it.
Ninety-day cycles are brilliant for execution: a product launch, customer problem, manufacturing bottleneck, commercial experiment or process failure. They force action and expose whether a team is producing outcomes or merely preparing slides about outcomes.
They are less useful as a substitute for long-term thinking.
Drug development, agricultural science, manufacturing capacity, brand trust and regulatory relationships do not fit neatly into quarterly bursts of enthusiasm. Bayer’s $2.2 billion Ohio investment is proof of that. Serious businesses need a long horizon for capital allocation, talent development and research, even while teams operate in short, disciplined sprints.
The trick is to run both clocks at once.
The executive team owns the five- to ten-year bets: where to invest, which capabilities to build, what not to pursue, and what risks are unacceptable. Teams own the next 90 days: what can move now, what must be tested, what has stalled, and who is accountable.
Confuse those two timeframes and you get either bureaucracy or corporate ADHD. Neither makes you money.
What this means for you
You do not need to sack 70% of your managers tomorrow. Frankly, if that is the first thing you take from this, you have missed the point.
But you should steal the discipline behind Bayer’s move.
First, map your five most important decisions. For each one, write down who currently makes it, who actually has the best information, how long it takes, and how many people can veto it. You will find at least one decision that has been crawling through a pointless approval maze for years.
Second, audit every recurring meeting. If a meeting exists mainly so managers can report information that could live in a dashboard or a one-page update, kill it. Give the time back to people doing useful work.
Third, stop rewarding people with management jobs just because they are talented. Build senior individual-contributor paths with real status and real money. Not everybody should manage people. Plenty of people should be paid handsomely to remain excellent at their craft.
Fourth, give teams a clear commercial scoreboard. Authority without numbers is just a pep talk. If you want people to make better decisions, they need to see revenue, margin, customer retention, delivery speed, quality and cash — whatever actually drives your business.
Finally, make indecision visible. When a call sits unresolved for two weeks, do not call it alignment. Call it what it is: a leadership failure.
Bill Anderson has made Bayer a live experiment in whether a giant company can become less managerial and more effective at the same time. The early evidence says the surgery has worked. The next phase — turning speed into durable growth — is where the real money is.
That is the bit every founder, investor and operator should watch. Cutting layers gets headlines. Building a business where fewer people make better decisions gets results.